Oculus Innovative Sciences to Present at Rodman & Renshaw Global Healthcare Conference

Download as PDF

PETALUMA, Calif.--(BUSINESS WIRE)--

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) today announced that Hoji Alimi, president and chief executive officer of Oculus, will present at the Rodman & Renshaw Global Healthcare Conference on Tuesday, May 15, 2007 at 8:00 a.m. local time (2:00 a.m. Eastern Time). The conference is being held at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. Mr. Alimi will present a corporate overview and update investors on recent clinical developments and international partnership agreements. A live broadcast of this presentation can be accessed at: www.wsw.com/webcast/rrshq11/ocls.

Connect to this webcast several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary. An archived recording will be available for 30 days following the live presentation at: ir.oculusis.com/releases.cfm.

Additionally, Robert Miller, chief financial officer of Oculus, will present the Oculus story to investors at the Brean Murray Carret 2007 Healthcare Conference on Tuesday, May 15, 2007 at the Grand Hyatt Hotel in New York City.

About Oculus

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of Microcyn(R) Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus' platform technology, called Microcyn, is a non-irritating oxychlorine compound designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.

Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V. Our website is www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, the matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are identified by the use of words such as "intended," and "designed," among others. These forward-looking statements are based on Oculus Innovative Sciences, Inc.'s current expectations. Investors are cautioned that such forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business including risks inherent in the development and commercialization of potential products, the risk that scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, the Company's future capital needs, and its ability to obtain additional funding and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the quarterly report on Form 10-Q for the quarter ended December 31, 2006. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements.

Oculus and Microcyn are trademarks or registered trademarks of Oculus Innovative Sciences, Inc.

Source: Oculus Innovative Sciences, Inc.

Released May 9, 2007